Thermo Fisher to acquire Brammer Bio for $1.7B in cash
Thermo Fisher and Brammer Bio announced they have entered into a definitive agreement under which Thermo Fisher will acquire Brammer Bio for approximately $1.7B in cash. Brammer Bio is a viral vector contract development and manufacturing organization. The business has nearly 600 employees at primary locations in Massachusetts and Florida. Brammer Bio is on track to deliver $250M of revenue in 2019 and expects to continue to exceed the projected market growth rate of 25% over the mid-term. Thermo Fisher expects the business to be accretive to adjusted EPS by 10c in the first full year of ownership. The transaction, which is expected to be completed by the end of Q2, is subject to customary closing conditions, including regulatory approvals. Upon completion, Brammer Bio will become part of Thermo Fisher's pharma services business within its Laboratory Products and Services Segment.